跳至主要内容
临床试验/JPRN-jRCTs071210035
JPRN-jRCTs071210035招募中2 期

Induction of remission and consolidation therapy using ATRA and ATO for acute promyelocytic leukemia - JSCT APL2021 - - - JSCT APL2021

Takase Ken0 个研究点目标入组 90 人开始时间: 2021年6月18日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 15age old 至 <= 75age old(—)
性别
All

入选标准

  • 1) Acute promyelocytic leukemia (APL) cases morphologically diagnosed as AML M3 or AML M3 variant.
  • 2) Initial treatment cases not receiving chemotherapy and radiation therapy.
  • 3) Cases aged between 15 and 75 years old at the time of obtaining consent.
  • 4) Perfomance status (ECOG): 0 to 2 cases.
  • 5) Cases that are expected to survive for 3 months or longer.
  • 6) Cases without serious organ damage.
  • 7) Cases in which written consent has been obtained from the patient after explaining the content of this study. However, in the case of minors, cases in which written consent has been obtained from the substitute and the person.

排除标准

  • 1) Cases with active double cancer.
  • 2) Cases with infectious diseases that are difficult to control.
  • 3) Cases with severe mental disorders.
  • 4) Cases of pregnancy or ongoing lactation.
  • 5) In addition, cases that the doctor in charge judged to be inappropriate.

研究者

发起方
Takase Ken

相似试验